Cargando…

Phase I study of glasdegib (PF‐04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies

The hedgehog signaling pathway regulates multiple morphogenetic processes during embryogenesis. Aberrant activation of the hedgehog pathway signal transduction in adult tissues is associated with the pathogenesis of hematologic malignancies and solid tumors. We report findings from an open‐label, mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minami, Yosuke, Minami, Hironobu, Miyamoto, Toshihiro, Yoshimoto, Goichi, Kobayashi, Yukio, Munakata, Wataru, Onishi, Yasushi, Kobayashi, Masahiro, Ikuta, Mari, Chan, Geoffrey, Woolfson, Adrian, Ono, Chiho, Shaik, Mohammed Naveed, Fujii, Yosuke, Zheng, Xianxian, Naoe, Tomoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543507/ https://www.ncbi.nlm.nih.gov/pubmed/28556364 http://dx.doi.org/10.1111/cas.13285

Ejemplares similares

Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
por: Shaik, Naveed, et al.
Publicado: (2019)

Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
por: Shaik, Naveed, et al.
Publicado: (2018)

The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells
por: Giordani, Giorgia, et al.
Publicado: (2016)

Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers
por: Shaik, Naveed, et al.
Publicado: (2021)

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors
por: Lin, Swan, et al.
Publicado: (2019)

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure
por: Lin, Swan, et al.
Publicado: (2020)

Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies
por: Ruiz‐Garcia, Ana, et al.
Publicado: (2020)

Clinical and Model‐Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study
por: Masters, Joanna C., et al.
Publicado: (2020)

Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single‐Dose, Matched Case‐Control Study
por: Masters, Joanna C., et al.
Publicado: (2020)

Potent antiproliferative effect of fatty‐acid derivative AIC‐47 on leukemic mice harboring BCR‐ABL mutation
por: Shinohara, Haruka, et al.
Publicado: (2019)

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)

Functionally Deregulated AML1/RUNX1 Cooperates with BCR-ABL to Induce a Blastic Phase-Like Phenotype of Chronic Myelogenous Leukemia in Mice
por: Yamamoto, Kiyoko, et al.
Publicado: (2013)

Small‐molecule Hedgehog inhibitor attenuates the leukemia‐initiation potential of acute myeloid leukemia cells
por: Fukushima, Nobuaki, et al.
Publicado: (2016)

Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia
por: Thompson, Daniel L., et al.
Publicado: (2020)

Glasdegib Dimaleate: Synthesis, Characterization and Comparison of Its Properties with Monomaleate Analogue
por: Peklar, Boris, et al.
Publicado: (2022)

The Role of Smoothened in Cancer
por: Jeng, Kuo-Shyang, et al.
Publicado: (2020)

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Cortes, Jorge E., et al.
Publicado: (2018)

Cytarabine/glasdegib: COVID-19 infection and CNS haemorrhage: 2 case reports
Publicado: (2021)

Impact of the Smoothened Inhibitor, IPI-926, on Smoothened Ciliary Localization and Hedgehog Pathway Activity
por: Peluso, Marisa O., et al.
Publicado: (2014)

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
por: Iyer, Sunil Girish, et al.
Publicado: (2022)

Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations
por: GALIMBERTI, FABRIZIO, et al.
Publicado: (2012)

Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors
por: Pietrobono, Silvia, et al.
Publicado: (2018)

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
por: Sekeres, Mikkael A., et al.
Publicado: (2023)

Oxysterols are allosteric activators of the oncoprotein Smoothened
por: Nachtergaele, Sigrid, et al.
Publicado: (2012)

Mechanisms of Smoothened Regulation in Hedgehog Signaling
por: Zhang, Jie, et al.
Publicado: (2021)

Smoothened gene alterations in keratocystic odontogenic tumors
por: Rui, Zhang, et al.
Publicado: (2014)

Regulation of Smoothened Trafficking and Abundance in Hedgehog Signaling
por: Jia, Jianhang, et al.
Publicado: (2022)

Cervical Spondylotic Amyotrophy: Case Series and Review of the Literature
por: Takahashi, Toshiyuki, et al.
Publicado: (2019)

Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
por: Terao, Toshiki, et al.
Publicado: (2019)

Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
por: Miyamoto, Kenichi, et al.
Publicado: (2020)

Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01
por: Miyamoto, Kenichi, et al.
Publicado: (2019)

Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance
por: Yoshimaru, Ryo, et al.
Publicado: (2023)

KEK-PF slow-positron facility
por: Shidara, T, et al.
Publicado: (1996)

NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia
por: Kakiuchi, Seiji, et al.
Publicado: (2017)

Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists
por: Relias, Valerie, et al.
Publicado: (2020)

Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
por: Zucenka, Andrius, et al.
Publicado: (2021)

Effect of home-based rehabilitation of purposeful activity-based electrical stimulation therapy for chronic stroke survivors: a crossover randomized controlled trial
por: Minami, Seigo, et al.
Publicado: (2021)

Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia
por: Chi, Sung-Gi, et al.
Publicado: (2022)

Smoothened as a new therapeutic target for human osteosarcoma
por: Hirotsu, Masataka, et al.
Publicado: (2010)

Roughing up Smoothened: chemical modulators of Hedgehog signaling
por: King, Randall W
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_ep48imd1771vkj846utf87t0d3